“PF-06647020”的意思、由来-开放百科全书

词条

PF-06647020

释义

References

{{Orphan|date=September 2017}}{{mergeto|Cofetuzumab pelidotin|date=October 2018}}PF-06647020 is an experimental antibody-drug conjugate in development for the treatment of cancer. It was created by Stemcentrx and is being developed by Pfizer. The drug is an anti-PTK7 monoclonal antibody linked to Auristatin-0101, an auristatin microtubule inhibitor.^[1]^[2]

Antibody-drug conjugates use a monoclonal antibody that binds to tumors cells linked to a cytotoxic drug. This allows the drug to selectively target the cells that the antibody binds to.

PTK7 is expressed by many tumors, including ovarian cancer, breast cancer, and non-small cell lung cancer.^[3] Early clinical trial results show a 50% response rate in patients with triple negative breast cancer and an almost complete response in ovarian tumors resistant to platinum-based chemotherapies.^[4]

References

1. ^{{cite web|url=http://adcreview.com/tag/pf-06647020/ |title=PF-06647020 Archives – ADC Review ADC Review |publisher=Adcreview.com |date= |accessdate=2017-05-22}}
2. ^{{cite web|url=http://adcreview.com/pfizer-adc-development-overview-2016/ |title=Pfizer Oncology: ADC Development Overview (2016) – ADC Review ADC Review |publisher=Adcreview.com |date= |accessdate=2017-05-22}}
3. ^http://www.pfizer.com/files/news/esmo/ESMO2016_Oncology_Technologies_Fact_Sheet_ADC.pdf
4. ^{{cite web|last=Patrick |first=Margaret |url=http://marketrealist.com/2016/06/abbvie-expects-ptk7-targeted-drug-enhance-oncology-capabilities/ |title=Why AbbVie Expects PTK7 to Enhance Its Oncology Capabilities |publisher=Market Realist |date=2016-06-28 |accessdate=2017-05-22}}

1 : Experimental cancer drugs

随便看

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。